A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pacific Biosciences Of California, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 147,700 shares of PACB stock, worth $370,726. This represents 0.0% of its overall portfolio holdings.

Number of Shares
147,700
Previous 105,300 40.27%
Holding current value
$370,726
Previous $394,000 48.73%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.36 - $3.65 $786,235 - $2.11 Million
-578,114 Reduced 39.0%
904,201 $1.24 Million
Q1 2024

May 15, 2024

BUY
$3.52 - $9.59 $3.3 Million - $8.99 Million
937,811 Added 172.23%
1,482,315 $5.56 Million
Q4 2023

Feb 14, 2024

SELL
$5.97 - $10.36 $15.5 Million - $26.9 Million
-2,600,173 Reduced 82.68%
544,504 $5.34 Million
Q3 2023

Nov 14, 2023

SELL
$8.23 - $13.93 $6.39 Million - $10.8 Million
-776,626 Reduced 19.81%
3,144,677 $26.3 Million
Q2 2023

Aug 14, 2023

SELL
$9.97 - $14.05 $11.2 Million - $15.8 Million
-1,127,669 Reduced 22.33%
3,921,303 $52.2 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $12.02 $3.75 Million - $5.68 Million
472,312 Added 10.32%
5,048,972 $58.5 Million
Q4 2022

Feb 14, 2023

SELL
$5.67 - $11.2 $2.03 Million - $4.01 Million
-358,452 Reduced 7.26%
4,576,660 $37.4 Million
Q3 2022

Nov 14, 2022

BUY
$3.93 - $8.57 $18.2 Million - $39.6 Million
4,619,581 Added 1464.07%
4,935,112 $28.6 Million
Q2 2022

Aug 15, 2022

SELL
$4.02 - $10.43 $7.77 Million - $20.2 Million
-1,932,718 Reduced 85.97%
315,531 $1.4 Million
Q1 2022

May 16, 2022

BUY
$8.43 - $20.9 $16 Million - $39.6 Million
1,893,895 Added 534.46%
2,248,249 $20.5 Million
Q4 2021

Feb 14, 2022

SELL
$19.26 - $30.08 $973,573 - $1.52 Million
-50,549 Reduced 12.48%
354,354 $7.25 Million
Q3 2021

Nov 15, 2021

BUY
$24.86 - $35.02 $3.44 Million - $4.84 Million
138,246 Added 51.84%
404,903 $10.3 Million
Q2 2021

Aug 16, 2021

SELL
$22.3 - $36.02 $2.11 Million - $3.4 Million
-94,484 Reduced 26.16%
266,657 $9.32 Million
Q1 2021

May 17, 2021

BUY
$26.38 - $51.15 $8.69 Million - $16.9 Million
329,583 Added 1044.37%
361,141 $12 Million
Q4 2020

Feb 16, 2021

SELL
$10.5 - $28.5 $2.87 Million - $7.8 Million
-273,698 Reduced 89.66%
31,558 $819,000
Q3 2020

Nov 16, 2020

BUY
$3.61 - $9.87 $482,306 - $1.32 Million
133,603 Added 77.83%
305,256 $3.01 Million
Q2 2020

Aug 14, 2020

BUY
$2.65 - $4.03 $158,350 - $240,812
59,755 Added 53.4%
171,653 $592,000
Q1 2020

May 15, 2020

BUY
$2.36 - $5.26 $190,093 - $423,682
80,548 Added 256.93%
111,898 $342,000
Q4 2019

Feb 14, 2020

BUY
$4.6 - $5.57 $57,495 - $69,619
12,499 Added 66.3%
31,350 $161,000
Q3 2019

Nov 14, 2019

SELL
$4.99 - $6.16 $21.6 Million - $26.7 Million
-4,333,652 Reduced 99.57%
18,851 $97,000
Q2 2019

Feb 14, 2020

BUY
$5.92 - $7.41 $25.4 Million - $31.8 Million
4,287,701 Added 6616.62%
4,352,503 $26.3 Million
Q2 2019

Aug 14, 2019

SELL
$5.92 - $7.41 $15.3 Million - $19.1 Million
-2,581,863 Reduced 97.55%
64,802 $392,000
Q1 2019

May 15, 2019

BUY
$6.8 - $7.4 $17.9 Million - $19.4 Million
2,626,918 Added 13302.87%
2,646,665 $0
Q4 2018

Feb 14, 2019

SELL
$3.99 - $7.82 $135,045 - $264,675
-33,846 Reduced 63.15%
19,747 $146,000
Q3 2018

Nov 13, 2018

SELL
$3.52 - $5.55 $2.1 Million - $3.31 Million
-597,075 Reduced 91.76%
53,593 $0
Q2 2018

Aug 10, 2018

BUY
$2.11 - $3.92 $378,156 - $702,546
179,221 Added 38.02%
650,668 $0
Q1 2018

May 11, 2018

BUY
$2.05 - $3.23 $722,573 - $1.14 Million
352,475 Added 296.27%
471,447 $967,000
Q4 2017

Feb 09, 2018

BUY
$2.59 - $5.44 $259,626 - $545,316
100,242 Added 535.19%
118,972 $314,000
Q3 2017

Nov 09, 2017

BUY
$3.2 - $5.57 $59,936 - $104,326
18,730
18,730 $98,000

Others Institutions Holding PACB

About PACIFIC BIOSCIENCES OF CALIFORNIA, INC.


  • Ticker PACB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 224,840,992
  • Market Cap $564M
  • Description
  • Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits design...
More about PACB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.